Early-stage results for a new approach to fighting cancer are sparking investors' optimism.
News & Analysis: NantKwest
News that a law firm is investigating the company's board of directors for possible breaches of their fiduciary duty causes shares to tank.
The stock market didn't move much today, but these stocks lost a lot of ground. Find out why.
NantKwest gets the green light from the FDA to start clinical trials for its new cancer vaccine.
These two biotech stocks are down big in 2016. Which is the better pick now?
Patrick Soon-Shiong is the planet's richest doctor. He also has a track record that includes the multibillion-dollar sales of two companies, which suggests investors might not want to ignore his latest venture.
These been-there-done-that leaders are at the helm of four different emerging companies that investors should be paying attention to.
Kite Pharma, NantKwest, and Editas Medicine are working on game-changing ways to fight back against cancer.
Both biotech stocks have fallen heavily over the past year. See which is a better buy now.
An accounting error caused the immunotherapy specialist's shares to briefly drop on Friday.